Cortagen

Cortagen (AEDP) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro, developed through directed synthesis based on amino acid analysis of the natural brain cortex peptide preparation Cortexin. It belongs to the Khavinson peptide family of short bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology.

Cortagen's mechanism of action involves tissue-specific modulation of gene expression in the central nervous system. Microarray studies have revealed that Cortagen influences the expression of genes involved in transcriptional regulation, chromatin organization, and inflammatory pathway balance. The peptide exhibits anti-inflammatory properties by reducing oxidative stress in brain tissue, which is relevant for recovery from neurological insults such as stroke or traumatic brain injury. Its small size and specific amino acid composition allow passage across the blood-brain barrier.

Research has demonstrated Cortagen's effects on cardiac and neural gene expression using microarray analysis in mouse models. Studies show it modulates genes involved in signal transduction, immune response, and cell differentiation in brain tissue. The peptide has been studied for neuroprotective applications including stroke recovery, cognitive decline, and neurodegenerative conditions. As a member of the bioregulatory peptide family, Cortagen is often studied alongside other Khavinson peptides (Epithalon, Pinealon) that target specific organ systems, representing a class of compounds that may regulate tissue function through epigenetic mechanisms.